JAK3/FLT3/PDGFR inhibitors (Crystal Genomics)

N/A

Report date: 2025/03/20 20:00:06

NME

Base Information

Drug NameJAK3/FLT3/PDGFR inhibitors (Crystal Genomics)

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionTyrosine-protein kinase JAK3 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitorsPlatelet-derived growth factor receptor inhibitors

TargetsTyrosine-protein kinase JAK3Tyrosine-protein kinase receptor FLT3Platelet-derived growth factor receptor

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesCrystalgenomics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCrystalgenomics Inc

Active IndicationsN/A

Inactive IndicationsMelanoma

Other Information

ATC CodeN/A